^
    Back
    Association details:
    Biomarker:SDHC mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:dasatinib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood

    Published date:
    07/17/2020
    Excerpt:
    In addition, patients with SDHC and TMEM127 copy number loss had longer OS (P  = .035, .006) compared with patients with normal copy number.
    DOI:
    10.1002/cam4.3319